AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36484844 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 34
Study 33270115 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 10
Study 33270115 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 33271112 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative endocrine therapy
Number of subjects: 0
Study 33271112 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34077243 — intervention group
Group type: EXPERIMENTAL
Intervention: Light massage
Number of subjects: 104
Study 34077243 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 104
Study 34077243 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 104
Study 99050129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (80 mg/70 kg, p.o.)
Number of subjects: 5
Study 99050129 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (5, 10, 20 mg/70 kg, p.o.)
Number of subjects: 5
Study 99050129 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150, 300, 600 mg/70 kg, p.o.)
Number of subjects: 5
Study 99050129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 32827162 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflapegrastim (fixed dose of 13.2 mg, 3.6 mg G-CSF)
Number of subjects: 669
Study 32827162 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg G-CSF)
Number of subjects: 669
Study 32421480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitz bath with ozonised water (Group O)
Number of subjects: 80
Study 32421480 — intervention group
Group type: COMPARATOR
Intervention: Sitz bath with ordinary tap water (Group T)
Number of subjects: 80
Study 33317434 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based therapeutic approaches for treating sexual dysfunctions among CSA survivors
Number of subjects: 0
Study 33317434 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically tested therapeutic approaches for treating sexual problems among CSA survivors
Number of subjects: 0
Study 36414015 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted training
Number of subjects: 50
Study 36414015 — intervention group
Group type: COMPARATOR
Intervention: Theoretical training
Number of subjects: 50
Study 33598693 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 54
Study 32758233 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp delivered by community health workers (CHWs)
Number of subjects: 734
Study 32758233 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (IPTp delivered at health facilities)
Number of subjects: 734
Study 35525430 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay
Number of subjects: 3875
Study 35525430 — intervention group
Group type: COMPARATOR
Intervention: Control group (HPV DNA‒negative on day 1)
Number of subjects: 3875
Study 33946029 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (80 mg daily for 8 weeks)
Number of subjects: 40
Study 33946029 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (running on treadmill for 8 weeks, 3 sessions per week, 45-60 min per session)
Number of subjects: 40
Study 33946029 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation + Endurance training
Number of subjects: 40
Study 33946029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation or exercise)
Number of subjects: 40
Study 34256720 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training course on healthy beverages standards (AB 2084)
Number of subjects: 43
Study 34247409 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing regimen (higher dose)
Number of subjects: 0
Study 34247409 — intervention group
Group type: COMPARATOR
Intervention: Low dose (control)
Number of subjects: 0
Study 32800815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold intervention (ventricular index of >p97 and anterior horn width of >6 mm)
Number of subjects: 126
Study 32800815 — intervention group
Group type: COMPARATOR
Intervention: High threshold intervention (ventricular index of >p97 + 4 mm and anterior horn width of >10 mm)
Number of subjects: 126
Study 32800815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold intervention
Number of subjects: 126
Study 32800815 — intervention group
Group type: COMPARATOR
Intervention: High threshold intervention with ventriculoperitoneal shunt
Number of subjects: 126
Study 32800815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold intervention with ventriculoperitoneal shunt
Number of subjects: 126
Study 36098907 — intervention group
Group type: EXPERIMENTAL
Intervention: Revisional Roux-en-Y gastric bypass (RYGB)
Number of subjects: 160
Study 36098907 — intervention group
Group type: EXPERIMENTAL
Intervention: Revisional One-Anastomosis gastric bypass (OAGB)
Number of subjects: 160
Study 36098907 — intervention group
Group type: COMPARATOR
Intervention: One-Anastomosis gastric bypass (OAGB)
Number of subjects: 160
Study 36098907 — intervention group
Group type: COMPARATOR
Intervention: Both groups (RYGB and OAGB)
Number of subjects: 160
Study 33838658 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered antenatal care (PCANC)
Number of subjects: 2150
Study 33838658 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control group)
Number of subjects: 2150
Study 33838658 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 2150
Study 33838658 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater parity
Number of subjects: 2150
Study 33838658 — intervention group
Group type: EXPERIMENTAL
Intervention: Burera district
Number of subjects: 2150
Study 32124167 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 randomly selected primer pairs for validation and genetic diversity study
Number of subjects: 36
Study 35385061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical Ablation (MOCA)
Number of subjects: 167
Study 35385061 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate Adhesive (CAE)
Number of subjects: 167
Study 35385061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MOCA and CAE
Number of subjects: 167
Study 32522771 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery (Arm A): three cycles of paclitaxel and cisplatin followed by type C radical hysterectomy and pelvic ± paraaortic lymphadenectomy.
Number of subjects: 240
Study 32522771 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (Arm B): definitive concurrent chemoradiotherapy including external beam pelvic radiotherapy combined with concurrent weekly cisplatin followed by brachytherapy.
Number of subjects: 240
Study 33085170 — intervention group
Group type: EXPERIMENTAL
Intervention: DIVAVIVA medium
Number of subjects: 0
Study 33085170 — intervention group
Group type: COMPARATOR
Intervention: Restylane Perlane Lidocaine
Number of subjects: 0
Study 33085170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 33081788 — intervention group
Group type: EXPERIMENTAL
Intervention: <5% fibrosis
Number of subjects: 228
Study 33081788 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to <10% fibrosis
Number of subjects: 228
Study 33081788 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥10% fibrosis
Number of subjects: 228
Study 33081788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis proportion
Number of subjects: 228
Study 35546450 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide (n=874)
Number of subjects: 1748
Study 35546450 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily insulin aspart (IAsp) (n=874)
Number of subjects: 1748
Study 35546450 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 1748
Study 35546450 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily insulin aspart (IAsp)
Number of subjects: 1748
Study 33044411 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific intervention (plasma transfusion, low‐dose unfractionated heparin, and tranexamic acid)
Number of subjects: 80
Study 33829317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 44
Study 33829317 — intervention group
Group type: COMPARATOR
Intervention: Control group (therapeutic exercise only)
Number of subjects: 44
Study 33829317 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HILT and Control
Number of subjects: 44
Study 33896590 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced normothermia (maintaining core temperature at 37°C using external cooling, cold i.v. fluids, and medications like buspirone, clonidine, and magnesium sulphate)
Number of subjects: 12
Study 33896590 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced normothermia
Number of subjects: 12
Study 33896590 — intervention group
Group type: COMPARATOR
Intervention: Control (fever group)
Number of subjects: 12
Study 36178169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose green tea extract (843 mg/day EGCG)
Number of subjects: 1075
Study 34183565 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 1 mg tablets
Number of subjects: 20
Study 34183565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol plus micronized progesterone (MP)
Number of subjects: 20
Study 34183565 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol alone
Number of subjects: 20
Study 32164631 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT intervention (2 sessions/week of low-intensity cycling with 'all-out' sprints, increasing from 10 to 20 seconds over 6 weeks)
Number of subjects: 25
Study 32164631 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 25
Study 32164631 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT intervention
Number of subjects: 25
Study 35567872 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa oil 1000 mg/day for 8 weeks
Number of subjects: 44
Study 35567872 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 44
Study 34110902 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise
Number of subjects: 0
Study 34110902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32121339 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g dark chocolate bar
Number of subjects: 18
Study 32121339 — intervention group
Group type: COMPARATOR
Intervention: 100 g white chocolate bar
Number of subjects: 18
Study 35554361 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated TMS (nTMS)
Number of subjects: 18
Study 35554361 — intervention group
Group type: COMPARATOR
Intervention: Manual hotspot technique
Number of subjects: 18
Study 32465723 — intervention group
Group type: COMPARATOR
Intervention: RVAD utilization in pre-approval era (N=67)
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: RVAD utilization in post-approval era (N=107)
Number of subjects: 174
Study 32465723 — intervention group
Group type: COMPARATOR
Intervention: Unplanned RVAD in pre-approval era (N=67)
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned RVAD in post-approval era (N=107)
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of CVVHD
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-LVAD length of stay
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implant survival
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from gastrointestinal bleeding
Number of subjects: 174
Study 32465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from stroke
Number of subjects: 174
Study 35089358 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (10-Hz transcranial magnetic stimulation) for 6 weeks
Number of subjects: 34
Study 35089358 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS for 6 weeks
Number of subjects: 34
Study 35089358 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with TRD
Number of subjects: 34
Study 35089358 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with MDD
Number of subjects: 34
Study 33507691 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + radiation therapy
Number of subjects: 20
Study 33507691 — intervention group
Group type: COMPARATOR
Intervention: Placebo + radiation therapy
Number of subjects: 20
Study 35717243 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security (COS) approach adapted to the childcare setting (COS-Classroom)
Number of subjects: 113
Study 35717243 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 113
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology for 8 weeks
Number of subjects: 347
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology for 4 weeks followed by MP for 4 weeks if no response to reflexology
Number of subjects: 347
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: MP for 8 weeks
Number of subjects: 347
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: MP for 4 weeks followed by reflexology for 4 weeks if no response to MP
Number of subjects: 347
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding reflexology after the first 4 weeks of MP
Number of subjects: 347
Study 35378595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding either intervention compared to continuing the same one
Number of subjects: 347
Study 35378595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study 34187938 — intervention group
Group type: EXPERIMENTAL
Intervention: LARS synthetic ligament
Number of subjects: 20
Study 34187938 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 20
Study 32681455 — intervention group
Group type: EXPERIMENTAL
Intervention: cerebellar intermittent theta burst stimulation (c‐iTBS) combined with vestibular rehabilitation (VR)
Number of subjects: 20
Study 32681455 — intervention group
Group type: COMPARATOR
Intervention: sham intermittent theta burst stimulation (sham iTBS) combined with vestibular rehabilitation (VR)
Number of subjects: 20
Study 32681455 — intervention group
Group type: COMPARATOR
Intervention: vestibular rehabilitation (VR)
Number of subjects: 20
Study 34340708 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 IU/day oral vitamin D3 for 12 weeks
Number of subjects: 191
Study 33160798 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (12-month weight loss program)
Number of subjects: 66
Study 33160798 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (wait-list control)
Number of subjects: 66
Study 33160798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups after 12 months
Number of subjects: 66
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose direct acting oral anticoagulants (LDDOAC)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (W)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mgs BID (D)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mgs (R)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mgs BID (A)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (D)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (R)
Number of subjects: 9360
Study 34162485 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (A)
Number of subjects: 9360
Study 35064063 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media campaign for mothers aimed at reducing indoor tanning (IT)
Number of subjects: 869
Study 35064063 — intervention group
Group type: COMPARATOR
Intervention: Prescription drug misuse campaign (control)
Number of subjects: 869
Study 34719829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 34719829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 200
Study 32471854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting treatment (BeSt and IMPROVED)
Number of subjects: 987
Study 32471854 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-acting treatment (BeSt)
Number of subjects: 987
Study 32471854 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-acting monotherapy
Number of subjects: 987
Study 32471854 — intervention group
Group type: COMPARATOR
Intervention: Fast-acting treatment (BeSt)
Number of subjects: 987
Study 32471854 — intervention group
Group type: COMPARATOR
Intervention: Fast-acting treatment (IMPROVED)
Number of subjects: 987
Study 36161306 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (2g/day for 4 days)
Number of subjects: 120
Study 36161306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34765938 — intervention group
Group type: EXPERIMENTAL
Intervention: Early access to antiretroviral therapy (ART)
Number of subjects: 240
Study 34765938 — intervention group
Group type: COMPARATOR
Intervention: Late access to antiretroviral therapy (ART)
Number of subjects: 240
Study 36075590 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with intradermal needling
Number of subjects: 116
Study 36075590 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 116
Study 36075590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after treatment)
Number of subjects: 116
Study 32897010 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial therapy (ABT) + recombinant interferon alpha‐2b with antioxidant complex (vitamins E and C)
Number of subjects: 62
Study 32897010 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial therapy (ABT)
Number of subjects: 62
Study 35270910 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (AAA) with the same coil for test‐treat‐test phases (n = 22)
Number of subjects: 47
Study 35270910 — intervention group
Group type: COMPARATOR
Intervention: Active coil stimulation for tests and placebo coil stimulation for treatment (APA) (n = 15)
Number of subjects: 47
Study 35270910 — intervention group
Group type: COMPARATOR
Intervention: Realistic placebo coil stimulation for all three phases (PPP) (n = 10)
Number of subjects: 47
Study 35270910 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (AAA)
Number of subjects: 47
Study 32540320 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial canting wedges
Number of subjects: 38
Study 32540320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral canting wedges
Number of subjects: 38
Study 32540320 — intervention group
Group type: COMPARATOR
Intervention: Unmodified ski boots (control)
Number of subjects: 38
Study 33520912 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 45-54 years
Number of subjects: 1135
Study 33520912 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants living in Barranquilla
Number of subjects: 1135
Study 35842871 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the AVAglio trial (NCT00943826)
Number of subjects: 169
Study 32291164 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS Clinical Decision Display System (CDDS)
Number of subjects: 0
Study 32291164 — intervention group
Group type: COMPARATOR
Intervention: No CDDS (control)
Number of subjects: 0
Study 35177653 — intervention group
Group type: COMPARATOR
Intervention: ERM[08-10]
Number of subjects: 100
Study 35177653 — intervention group
Group type: COMPARATOR
Intervention: DG and UDA
Number of subjects: 100
Study 34759043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 34759043 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 32299820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carfilzomib (27 mg/m2) with dexamethasone
Number of subjects: 121
Study 32299820 — intervention group
Group type: COMPARATOR
Intervention: High-dose carfilzomib (56 mg/m2) with dexamethasone
Number of subjects: 121
Study 32299820 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to high-dose carfilzomib (56 mg/m2) after progression on low-dose
Number of subjects: 121
Study 32299820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 121
Study 32299820 — intervention group
Group type: COMPARATOR
Intervention: High-dose carfilzomib (56 mg/m2)
Number of subjects: 121
Study 32299820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carfilzomib (27 mg/m2)
Number of subjects: 121
Study 35452354 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable (polyester) suture
Number of subjects: 40
Study 35452354 — intervention group
Group type: COMPARATOR
Intervention: Absorbable (vicryl) suture
Number of subjects: 40
Study 32265061 — intervention group
Group type: EXPERIMENTAL
Intervention: DJT1116PG 20 mg once daily for 7 days
Number of subjects: 36
Study 32265061 — intervention group
Group type: EXPERIMENTAL
Intervention: DJT1116PG 50 mg once daily for 7 days
Number of subjects: 36
Study 32265061 — intervention group
Group type: EXPERIMENTAL
Intervention: DJT1116PG 100 mg once daily for 7 days
Number of subjects: 36
Study 32265061 — intervention group
Group type: EXPERIMENTAL
Intervention: DJT1116PG (all doses)
Number of subjects: 36
Study 32265061 — intervention group
Group type: COMPARATOR
Intervention: DJT1116PG
Number of subjects: 36
Study 35067389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (2 μg/kg)
Number of subjects: 49
Study 35067389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal water)
Number of subjects: 49
Study 33495576 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 500 IU/mL plus methylprednisolone (M + E group)
Number of subjects: 54
Study 33495576 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone (M group)
Number of subjects: 54